Justyna Jakubowska

Learn More
STI571 (imatinib mesylate; Gleevec) is an inhibitor that targets the tyrosine kinase activity of Bcr-Abl present in chronic myelogenous leukemia (CML) cells. Some preclinical studies have demonstrated that the combination of STI571 with chemotherapeutic drugs results in enhanced toxicity in Bcr-Abl-positive leukemias. We investigated the potential benefit(More)
We have evaluated how levels of predictors of the cardio-vascular risk such as: glucose, insulin, total cholesterol, high-density cholesterol, low-density cholesterol and trigly-cerides as well as adiponectin, fibrinogen, D-Dimers and CRP changed 24-28 weeks after treatment of hyperthyroid-ism in women with low and high titer of antibodies, and if their(More)
  • 1